SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biosource International
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DGMontana who wrote (675)9/28/1999 10:47:00 AM
From: Joe Dancy  Read Replies (1) of 696
 
David: I need to look again at exactly what IFCI said - but if you look at Dycom they languished for quite some time before they got their act together also, missed earnings, etc.

The one positive thing about IFCI is that the press release did note that backlogs were growing - which also occured just before DY took off.

Curious that you sent this note, I had seen the IFCI action and contemplated adding to the position after I review and see what is being said on the thread and what has been released and picked up by the press.

I know that the fund manager who orginally pointed this company out to me is no longer so hot on it - but then again he has to worry about quarter to quarter performance. IFCI is going no-where soon after this announcement so we have some time to watch IMO, and pick up the discarded pieces over the next quarter if we like what we see longer term.

The area IFCI is in is a growing one - just like BIOI - which also helps.

Back to BIOI - they have tenatively agreed to let us stream their next quarterly conference call so investors like us who work can listen - and I think BIOI is much closer now to moving ahead then it has been in some time. And biotech is returning to favor from those I talk to.

And a couple of other things to think about: Most in the market are essentially traders, not long term investors. These companies are selling at or very near book value, and generally have little debt. They are in growing segments of the economy. They are microcaps which to date have been ignored by institutions (but with the merger mania may not be ignored by competitors much longer). The large cap/small cap valuation ratio is at historic highs.

And couple of Nobel prize winners have done a historical study of the market and found that microcaps bought near book value tend to grossly outperform over time.

So much for the theory - I like both BIOI and IFCI - but your guess on where they may go short term is as good as mine. I'll check out the IFCI action on SI.

Joe
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News